Pharmacokinetics, Absorption and Tissue Distribution of Tanshinone IIA Solid Dispersion

Abstract

This study was designed to elucidate the pharmacokinetics, absorption, tissue distribution and plasma protein binding properties of tanshinone IIA, a highly lipophilic compound isolated from Salvia miltiorrhiza. Tanshinone IIA was isolated using a previously well developed LC-MS/MS method. Its pharmacokinetic characteristics, absolute bioavailability, tissue distribution and plasma protein binding properties were determined. The membrane permeability was evaluated using Caco-2 cells in monolayer. The pharmacokinetic plasma profile of tanshinone IIA after a single intravenous dosing exhibited a triexponential pattern consisting of rapid distribution (t _1/2 α, 0.024 h), slow redistribution (t _1/2 β, 0.34 h) and terminal elimination phase (t _1/2 γ, 7.5 h). Tanshinone IIA preferentially distributed into the reticuloendothelial system, especially into liver and lung, after either intravenous or oral doses. Tanshinone IIA (99.2 %) bound highly to plasma proteins, among which lipoprotein played an important role (77.5 %). Tanshinone IIA absorption was extremely poor with an absolute bioavailability below 3.5 %. Absorptive saturation was deduced from the fact that the AUC and C _max increased less proportionally to dose and t _max was significantly prolonged. The poor absorption of tanshinone IIA may be caused by its low aqueous solubility and limited membrane permeability. There were no significant differences of the apparent permeability coefficient for all tested concentrations and for the apical to basolateral and reverse direction transport, suggesting a passive transport mode and no involvement of an efflux protein. In conclusion, tanshinone IIA has a suitable pharmacokinetic behavior except for its poor absorption. A pharmaceutical strategy for promoting its absorption should be designed to develop tanshinone IIA as a new drug candidate.

Key words

Tanshinone IIA - pharmacokinetics - tissue distribution - absorption - protein binding

References

• 1 Cao E H, Liu X Q, Wang J J, Xu N F. Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells.  Free Radic Biol Med. 1996;  20 801-6
• 2 Li X H, Tang R Y. [Relationship between inhibitory action of tanshinone on neutrophil function and its prophylactic effects on myocardial infarction].  Zhongguo Yao Li Xue Bao. 1991;  12 269-72
• 3 Yuan S L, Wang X J, Wei Y Q. [Anticancer effect of tanshinone and its mechanisms].  Ai Zheng. 2003;  22 1363-6
• 4 Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J. et al . Potential anticancer activity of tanshinone IIA against human breast cancer.  Int J Cancer. 2005;  116 799-807
• 5 Wang X, Yuan S, Wang C. [A preliminary study of the anti-cancer effect of tanshinone on hepatic carcinoma and its mechanism of action in mice].  Zhonghua Zhong Liu Za Zhi. 1996;  18 412-4
• 6 Kim H H, Kim J H, Kwak H B, Huang H, Han S H, Han H. et al . Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge.  Biochem Pharmacol. 2004;  67 1647-56
• 7 Lam B Y, Lo A C, Sun X, Luo H W, Chung S K, Sucher N J. Neuroprotective effects of tanshinones in transient focal cerebral ischemia in mice.  Phytomedicine. 2003;  10 286-91
• 8 Xia W J, Yang M, Fok T F, Li K, Chan W Y, Ng P C. et al . Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage.  Pediatr Res. 2005;  58 784-90
• 9 Hao H, Wang G, Li P, Li J, Ding Z. Simultaneous quantification of cryptotanshinone and its active metabolite tanshinone IIA in plasma by liquid chromatography/tandem mass spectrometry (LC-MS/MS).  J Pharm Biomed Anal. 2006;  40 382-8
• 10 Chen F, Luo H W. Observation on the hydrophobic interaction of tanshinone IIA by transmission electron microscope.  J Chin Electr Microscop Soc. 2003;  22 16-20
• 11 Ezeh B, Haiman M, Alber H F, Kunz B, Paulweber B, Lingenhel A. et al . Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls.  J Lipid Res. 2003;  44 1523-9
• 12 Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.  Clin Ther. 2002;  24 2022-50
• 13 Bravo Gonzalez R C, Huwyler J, Walter I, Mountfield R, Bittner B. Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension.  Int J Pharm. 2002;  245 143-51
• 14 Kuchimanchi K R, Udata C, Johnston T P, Mitra A K. Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats.  Drug Metab Dispos. 2000;  28 403-8
• 15 Rivory L P, Pond S M, Winzor D J. The influence of pH on the interaction of lipophilic anthracyclines with bovine serum albumin. Quantitative characterization by measurement of fluorescence quenching.  Biochem Pharmacol. 1992;  44 2347-55
• 16 Demant E J, Jensen P B, Sehested M. Characterization of the cooperative cross-linking of doxorubicin N-hydroxysuccinimide ester derivatives to water soluble proteins.  Biochim Biophys Acta. 1991;  1118 83-90
• 17 Li P, Wang G J, Li J, Hao H P, Zheng C N. Characterization of metabolites of tanshinone IIA in rats by liquid chromatography/tandem mass spectrometry.  J Mass Spectrom. 2006;  41 670-84
• 18 Wasan K M, Ramaswamy M, McIntosh M P, Porter C J, Charman W N. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas.  J Pharm Sci. 1999;  88 185-90
• 19 Hughes T A, Gaber A O, Montgomery C E. Plasma distribution of cyclosporine within lipoproteins and ”in vitro” transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins.  Ther Drug Monit. 1991;  13 289-95
• 20 Wasan K M, Kennedy A L, Cassidy S M, Ramaswamy M, Holtorf L, Chou J W. et al . Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.  Antimicrob Agents Chemother. 1998;  42 3146-52
• 21 Amidon G L, Lennernas H, Shah V P, Crison J R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.  Pharm Res. 1995;  12 413-20